ENHANCEMENT BY PERFLUSION EMULSION (OXYGENT(R)) AND CARBOGEN BREATHING OF THE TUMOR-GROWTH DELAY OF THE FSAIIC FIBROSARCOMA AFTER TREATMENT WITH ANTITUMOR ALKYLATING-AGENTS

被引:9
作者
HOLDEN, SA [1 ]
TEICHER, BA [1 ]
HA, C [1 ]
ARA, G [1 ]
HERMAN, TS [1 ]
机构
[1] JOINT CTR RADIAT THERAPY,BOSTON,MA 02115
来源
BIOMATERIALS ARTIFICIAL CELLS AND IMMOBILIZATION BIOTECHNOLOGY | 1992年 / 20卷 / 2-4期
关键词
D O I
10.3109/10731199209119736
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Many anticancer drugs require oxygen to be cytotoxic, or are selectively cytotoxic toward cells under oxygenated conditions. The effects of the dilute perfluorochemical emulsion Fluosol-DA with a wide variety of chemotherapeutic agents have been explored; however, It has not been possible to determine the optimal level of circulating perfluorochemical emulsion with anticancer drugs because the volume of Fluosol that my be administered in limited. Using a concentrated 90% Perflubron emulsion, Oxygent(R), a wide range of perfluorochemical emulsion doses have been examined in combination with melphalan, cyclophosphamide and BCNU in a murine solid tumor model. When Oxygent was administered by injection i.v. just prior to the injection of melphalan (10 mg/kg), the greatest tumor growth delays were obtained with Oxygent levels between 4 and 12 g PFC/kg. With each of these drugs the greatest tumor growth delays were obtained when the drug was prepared in the emulsion and the combination injected i.v. In each case, each dose of drug was followed by 6 h. of breathing carbogen.
引用
收藏
页码:895 / 898
页数:4
相关论文
共 19 条
[1]   BIOLOGIC DISCUSSIONS AUGMENTING RADIATION EFFECTS AND MODEL SYSTEMS [J].
BUSH, RS ;
HILL, RP .
LARYNGOSCOPE, 1975, 85 (07) :1119-1133
[2]   EXPLOITATION OF OXYGEN ENHANCEMENT RATIO IN CLINICAL PRACTICE [J].
DUNCAN, W .
BRITISH MEDICAL BULLETIN, 1973, 29 (01) :33-38
[3]   TIME-DOSE RELATIONSHIPS IN RADIOTHERAPY [J].
FOWLER, JF ;
THOMLINSON, RH ;
HOWES, AE .
EUROPEAN JOURNAL OF CANCER, 1970, 6 (03) :207-+
[4]   HYPOXIC TUMOR-CELL - TARGET FOR SELECTIVE CANCER-CHEMOTHERAPY [J].
KENNEDY, KA ;
TEICHER, BA ;
ROCKWELL, S ;
SARTORELLI, AC .
BIOCHEMICAL PHARMACOLOGY, 1980, 29 (01) :1-8
[5]  
KENNEDY KA, 1981, BRISTOLMYERS CANCER, V2, P85
[6]  
SARTORELLI A C, 1988, Cancer Research, V48, P775
[7]  
TEICHER BA, 1987, CANCER TREAT REP, V71, P173
[8]   EFFECT OF FLUOSOL-DA/O-2 ON TUMOR-CELL AND BONE-MARROW CYTOTOXICITY OF NITROSOUREAS IN MICE BEARING FSA-II FIBROSARCOMA [J].
TEICHER, BA ;
HOLDEN, SA ;
ROSE, CM .
INTERNATIONAL JOURNAL OF CANCER, 1986, 38 (02) :285-288
[9]  
TEICHER BA, 1988, CANCER CHEMOTH PHARM, V21, P286
[10]   EFFECT OF FLUOSOL-DA ON THE RESPONSE OF INTRACRANIAL 9L TUMORS TO X-RAYS AND BCNU [J].
TEICHER, BA ;
HERMAN, TS ;
ROSE, CM .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1988, 15 (05) :1187-1192